A Rare Case of Spontaneous Renal Cholesterol Crystallization Embolism

0
0
0

A Rare Case of Spontaneous Renal Cholesterol Crystallization Embolism

Introduction to Cholesterol Crystal Embolism

Cholesterol crystal embolism (CCE) represents a systemic disorder characterized by the occlusion of small arteries due to embolized cholesterol crystals from ruptured atherosclerotic plaques. While frequently associated with iatrogenic triggers such as vascular interventions (coronary angiography, arterial stenting) or cardiovascular surgeries (aortic aneurysm repair, bypass grafting), spontaneous CCE remains exceptionally rare. Renal involvement occurs in approximately 50% of CCE cases, manifesting as acute or subacute kidney injury with variable clinical presentations. This article explores a diagnostically challenging case of spontaneous renal CCE in a 78-year-old male, emphasizing its atypical presentation, histopathological confirmation, and long-term management outcomes.

Clinical Presentation and Diagnostic Journey

The patient, a 78-year-old male with a decade-long history of type 2 diabetes and five years of hypertension managed with oral antihypertensives (amlodipine, valsartan), initially presented with proteinuria (0.44 g/24h) and acute kidney injury (serum creatinine 2.26 mg/dL). Two months prior to hospitalization, he had attempted dietary protein restriction without improvement. Notably absent were classic peripheral embolic signs: no livedo reticularis, digital ischemia, or blue toe syndrome.

Laboratory findings revealed mild anemia (hemoglobin 103 g/L), elevated eosinophils (8.3%), and a marginally increased erythrocyte sedimentation rate (21 mm/h). Lipid profile showed normal cholesterol (3.85 mmol/L) and triglyceride (1.06 mmol/L) levels. Imaging studies identified atherosclerotic plaques in carotid and lower extremity arteries via Doppler ultrasound, while cardiac echocardiography and abdominal CT urography showed no structural abnormalities.

The diagnostic pivot occurred through renal biopsy, which demonstrated pathognomonic features of CCE: two larger renal arteries exhibited near-complete occlusion by needle-shaped cholesterol clefts within thickened intimal layers (Figure 1). Periodic acid-Schiff and silver methenamine stains highlighted glomerulosclerosis in 2 of 7 sampled glomeruli, accompanied by mild interstitial fibrosis and tubular atrophy. Immunofluorescence revealed segmental IgM deposits in arterial walls, supporting the inflammatory component of atheroembolism.

Diagnostic Criteria and Clinical Challenges

This case met modified Scolari criteria for renal CCE:

  1. Acute kidney injury: 50% serum creatinine elevation from baseline (peaking at 3.50 mg/dL)
  2. Histopathological confirmation: Cholesterol clefts in renal arteries
  3. Spontaneous onset: Absence of precipitating intravascular procedures or trauma

The absence of cutaneous embolic phenomena and normal complement levels (C3, C4 within reference ranges) initially obscured the diagnosis. This underscores CCE’s capacity for “silent” renal involvement, where systemic inflammation markers (elevated ESR, eosinophilia) may serve as subtle clues. The 8.3% eosinophilia, while nonspecific, aligned with the inflammatory response to cholesterol crystal embolization.

Therapeutic Strategy and Longitudinal Outcomes

Management focused on three pillars:

  1. Risk factor modification:

    • Intensive glycemic control: Transition from oral agents to insulin (HbA1c reduced from 8.9% to 5.6%)
    • Blood pressure optimization: Combination therapy with clonidine (75 mg BID), arotinolol (10 mg BID), and benidipine (8 mg QD) achieving 110/70 mmHg
    • Statin therapy: Atorvastatin 20 mg nightly despite normal lipids, targeting plaque stabilization

  2. Renoprotective measures:

    • Protein-restricted diet (0.6 g/kg/day) with ketoanalog supplementation (Ketosteril)
    • Traditional Chinese medicine adjuvant: Corbrin capsules (1.0 g TID) for purported anti-fibrotic effects

  3. Avoidance of anticoagulation:

    • Deliberate exclusion of antiplatelet/anticoagulant agents to prevent further plaque disruption

Serial monitoring revealed a paradoxical creatinine trajectory: initial deterioration to 3.50 mg/dL (September 2014) followed by gradual improvement over 36 months, stabilizing at 0.90 mg/dL by September 2017. This biphasic pattern reflects the natural history of CCE—acute ischemia from crystal occlusion followed by partial vascular recanalization and compensatory hemodynamic adaptations.

Mechanistic Insights and Prognostic Considerations

Cholesterol crystals from unstable aortic/renal artery plaques trigger a dual pathology:

  1. Mechanical obstruction: Wedge-shaped crystals occlude distal arterioles (150-200 μm diameter), causing patchy cortical infarcts.
  2. Sterile inflammation: Crystal-activated NLRP3 inflammasome promotes IL-1β release, sustaining perivascular inflammation and fibrosis.

The patient’s favorable renal recovery contrasts with historical data showing progression to ESRD in 72%-79% of CCE cases. Several prognostic factors likely contributed:

  • Early histopathological diagnosis: Enabled timely withdrawal of nephrotoxic agents (ACE inhibitors)
  • Aggressive statin use: Pleiotropic effects beyond lipid-lowering, including plaque stabilization and anti-inflammatory actions
  • Absence of multivisceral involvement: Isolated renal embolism permitted focused management

Therapeutic Controversies and Evidence Gaps

This case illuminates ongoing debates in CCE management:

  1. Corticosteroid utility: Withheld here due to equivocal evidence, though some studies suggest short-term use for inflammatory flares.
  2. Statins in normolipidemic patients: Justified by the PROSPER trial rationale—lipid-independent plaque stabilization in high-risk elderly patients.
  3. Anticoagulation risks: Avoidance of heparin/warfarin prevented secondary embolic showers, aligning with Belenfant’s recommendations.

Notably, the 3-year creatinine normalization challenges the paradigm of inevitable CKD progression in CCE. Potential mechanisms include:

  • Collateral circulation development in renal microvasculature
  • Macrophage-mediated crystal phagocytosis and dissolution
  • Adaptive hyperfiltration in preserved nephrons

Preventive Implications and Clinical Vigilance

This case reinforces preventive strategies for high-risk populations:

  • Pre-procedural plaque screening: Doppler evaluation of aortic/iliac atherosclerosis before invasive angiography
  • Statin pre-treatment: Minimum 6-week course before elective vascular interventions
  • Eosinophil monitoring: Unexplained eosinophilia >5% in AKI should prompt CCE consideration

For spontaneous CCE, heightened suspicion is warranted in elderly patients with:

  • Rapidly progressive CKD + normal urine sediment
  • Discordance between atherosclerotic burden and renal function
  • Transient eosinophilia/hypocomplementemia

Conclusion

The presented case expands the clinical spectrum of renal CCE, demonstrating that spontaneous embolization can occur without classic peripheral signs or procedural triggers. Histopathological confirmation remains the diagnostic gold standard, particularly in normolipidemic patients with atypical presentations. The observed renal function recovery over three years challenges fatalistic prognoses, emphasizing the role of aggressive risk factor modification and statin therapy. This case underscores the necessity for clinicians to maintain high diagnostic suspicion for CCE in elderly patients with unexplained AKI, even in the absence of iatrogenic precipitants.

doi.org/10.1097/CM9.0000000000000078

Was this helpful?

0 / 0